News

Missing Iron Receptor Linked to Poor Prognosis of IPF Patients

Jun 03, 2019

Patients with idiopathic pulmonary fibrosis produce a large amount of abnormal airway immune cells lacking an iron receptor that plays an important role in defending the lungs against pollutants and microbes, a study shows.

International Open Source Imaging Consortium Launched to Advance IPF Diagnosis

May 31, 2019

An international group of experts and advocates in idiopathic pulmonary fibrosis and other interstitial lung diseases (ILDs) have joined to create the Open Source Imaging Consortium (OSIC), a not-for-profit effort to advance the diagnosis of these illnesses with the help of digital imaging and machine learning.

PRM-151 Slows Lung Function Decline up to 76 Weeks in IPF Patients, Extension Study Shows

May 24, 2019

Promedior‘s investigational therapy for idiopathic pulmonary fibrosis — PRM-151 — continues to benefit patients after 76 weeks of treatment, slowing the decline in lung function and exercise capacity, while maintaining a similar safety profile as previous studies of PRM-151, an extension study shows.

Breath Biomarkers Not Proven Useful in Distinguishing Among Different ILDs

May 20, 2019

Measuring three specific biomarkers — nitric oxide, PGE2, and 8‐isoprostane — in the exhaled breath condensates or bronchoalveolar lavage fluids of patients with different forms of interstitial lung disease or other lung diseases does not show diagnostic potential, a study suggests.

Has your insurer denied a medical claim? Stand up for your rights

May 17, 2019

While legislation is critical in preventing health plan barriers, consumers also play a role. By knowing their rights, appealing denials, and fighting back, patients can stand up for themselves. But first they need to know that is an option.